We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Eurofins Technologies

Eurofins Technologies, part of the Eurofins Scientific group, is a fast-growing, global provider of diagnostic test k... read more Featured Products: More products

Download Mobile App





Eurofins Launches CE-IVD Marked Rapid POC Testing Devices to Identify Past Exposure to COVID-19 in 10 Minutes

By LabMedica International staff writers
Posted on 02 Jul 2020
Eurofins Technologies (Budapest, Hungary) has launched CE-IVD marked rapid point-of-care testing devices to identify a person’s past exposure to COVID-19 (SARS-CoV-2) in only 10 minutes. More...


The serology-based, finger-prick tests detect virus antibodies with a sensitivity of 94.5% from 19 days following the onset of symptoms. The CE-IVD marked INgezim COVID-19 CROM dual-recognition immunochromatographic assays determine the presence of total antibodies (IgG, IgA and IgM) specific to SARS-CoV-2 in a single blood, serum, and plasma sample by using nucleoprotein (N protein) as an antigen for detection of virus antibodies. The N protein is one of the most abundant early-onset proteins of the virus and is highly immunogenic, making it a reliable antigen candidate for the diagnosis of SARS-CoV-2. The CE-IVD marked kits include all materials required to perform the finger-prick test. The analysis can be performed outside of the laboratory, representing significant cost and time savings compared to other labor- and equipment-intensive methods.

Additionally, Eurofins has also launched Eurofins COVID-19 Sentinel RT-PCR environmental surfaces tests which can contribute to detecting asymptomatic virus spreaders. Through a comprehensive range of testing solutions, including waste water testing, work environment surface testing and worn mask testing, Eurofins COVID-19 Sentinel provides an early warning of the presence of SARS-CoV-2 at a given site (e.g. a city, factories, education, government and public service sites, nursing homes), before the virus spreads too broadly. If positive results are found employees present in the rooms tested can be isolated and advised to get tested by clinical RT-PCR. The affordable, easily organized and non-invasive Eurofins COVID-19 Sentinel program allows governments and companies to early detect the presence of asymptomatic and pre-symptomatic virus carriers, at times before anyone is aware of the issue, and to assess effectiveness of workplace COVID-19 management plans.



Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
New
Repetitive Pipette
VWR® Stepper Pro
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.